• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    p16INK4a
    January 24, 2020
    IKK
    January 24, 2020
    1. … -1 CONVEYS TEMOZOLOMIDE RESISTANCE BY THE INHIBITING DNA DAMAGE RESPONSE PATHWAY THROUGH THE POLYCOMB REPRESSOR Bmi-1
    2. … and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV)-mediated Bmi-1 interference driven by Bmi-1 promoter for gastric …
    3. … butyrate inhibits migration and induces AMPK‐mTOR pathway‐dependent autophagy and ROS‐mediated apoptosis via the miR‐139‐5p/Bmi‐1 axis in human …
    4. … following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of Bmi-1 and immune responses to Bmi-1 …
    5. … inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128
    6. … regulates paclitaxel resistance of ovarian cancer cells-a potential of miR-194 by attenuating paclitaxel resistance through the down-regulation of oncogene Bmi-1
    7. … the centromere complex from HeLa interphase cells: UV‐damaged DNA binding protein 1 (DDB‐1) is a component of the CEN‐complex, while BMI‐1 is transiently co …
    8. … the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting Bmi-1
    9. … with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by Bmi-1
    10. 15 Evaluation of Expression of the Bmi-1 Stem Cell Marker in Sinonasal Melanomas and Its Correlation With the Expression of Cell Cycle Proteins
    11. 40. Bmi-1 GENE SILENCING INFLUENCES CELL ADHESION AND INVASIVE PROPERTIES OF MEDULLOBLASTOMA CELLS VIA INHIBITION OF BMP PATHWAY
    12. A death from cancer signature: Microarray analysis identifies the 11-gene Bmi-1-pathway signature predicting therapy failure and short survival of patients diagnosed …
    13. A novel Bmi-1 inhibitor QW24 for the treatment of stem-like colorectal cancer
    14. A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1
    15. A novel pathway involving Tcf-driven Bcl2 under regulation of Bmi-1 stem cell factor: Role in chemoresistance
    16. A regulatory Bmi 1/let‐7i/ERK 3 pathway controls the motility of head and neck cancer cells
    17. A retrospective review of the prognostic value of ALDH-1, Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma
    18. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes
    19. Abstract A130: Targeting Bmi-1 by the novel Bmi-1 inhibitor PTC596 in acute leukemia
    20. Abstract A261: NPV-LDE-225 (Erismodegib) inhibits human prostate cancer stem cell growth in NOD/SCID IL2γnull mice by regulating Bmi-1 and microRNA-128.
    21. Abstract LB-234: Bcl-2, a novel target of Bmi-1 (the stem cell associated factor), induced Wnt signaling: Implications on prostate cancer
    22. Abstract# 1073: Targeting Bmi-1 in prostate cancer stem cells
    23. Abstract# 2185: Ewing family tumors that do not over-express Bmi-1 are a distinct subclass that arise from alternate mechanisms of molecular transformation
    24. Abstract# 2564: Relationship of smoothened (SMO) and Bmi-1 expression to progression free survival and overall survival in patients with resected non-small cell lung …
    25. Abstract# 5604: Bmi-1 protects human oral epithelial cells from ionizing radiation
    26. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of Bmi-1, TIM-3 and CLL-1
    27. Adenovirus-delivered Bmi-1 shRNA
    28. Affect of All-trans Retinoic Acid on Expression of Bmi-1 in A431 Cell Line [J]
    29. Alexa Fluor® 488 Mouse Anti-Human Bmi-1
    30. Alexa Fluor® 647 Mouse Anti-Human Bmi-1
    31. Amplification and construction of its sense and antisense eukaryotic expression vector of transcriptional repressor Bmi-1 gene
    32. An old player on a new playground: Bmi-1 as a regulator of prostate stem cells
    33. Anti-aging and anti-osteoporosis effects of green teen polyphenol in a premature aging model of Bmi-1 knockout mice
    34. Anti-aging effect of transplanted amniotic membrane mesenchymal stem cells in a premature aging model of Bmi-1 deficiency
    35. Anti-proliferation effect of Bmi-1 in U937 cells with siRNA
    36. Antisense RNA-mediated suppression of Bmi-1 gene expression inhibits the proliferation of lung cancer cell line A549
    37. Association between Bmi-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in …
    38. Association between the Polycomb Group (PcG) Bmi-1 Gene Expression and Outcome in Chronic Myeloid Leukemia (CML) Patients Receiving Allogeneic Stem Cell …
    39. Association of ATM and BMI‐1 genetic variation with breast cancer risk in Han Chinese
    40. Association of Bmi-1 and p16 as prognostic factors for head and neck carcinomas
    41. Association of Bmi-1 expression with clinicopathological features and prognosis of colorectal cancer
    42. Association of Bmi-1 mRNA expression with differentiation, metastasis and prognosis of gastric carcinoma
    43. Association of Elevated Peripheral Blood Micronucleus Frequency and Bmi-1 mRNA Expression with Metastasis in Iranian Breast Cancer Patients
    44. Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma
    45. Attenuation of doxorubicin-induced cardiotoxicity by esculetin through modulation of Bmi-1 expression
    46. B-Cell Lymphoma Cells Overexpressing Bmi-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T …
    47. Biological effects of pyrroloquinoline quinone on liver damage in Bmi-1 knockout mice
    48. Bmi 1 is downregulated by the natural compound curcumin, but not by bisdemethoxycurcumin and dimethoxycurcumin
    49. BMI is an important driver of beta-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children.
    50. Bmi-1 absence causes premature brain degeneration
    51. Bmi-1 activation is crucial in hTERT-induced epithelial–mesenchymal transition of oral epithelial cells
    52. Bmi-1 and homologous recombination markers in human breast cancer
    53. Bmi-1 and survivin expression with clinicopathological correlation and prognostic impact in B and T/NK-cell non-Hodgkin lymphoma
    54. Bmi-1 as A Molecular Marker for Prognosis of Pediatric ALL
    55. Bmi-1 autoantibody as a new potential biomarker for cervical carcinoma
    56. Bmi-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma
    57. Bmi-1 blocks the TGF-β-mediated senescence
    58. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
    59. Bmi-1 confers adaptive radioresistance to KYSE-150R esophageal carcinoma cells
    60. Bmi-1 cooperates with Foxg1 to maintain neural stem cell self-renewal in the forebrain
    61. Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways
    62. Bmi-1 cooperates with human papillomavirus type 16 E6 to immortalize normal human oral keratinocytes
    63. Bmi-1 deficiency resulted in developmental defects in mouse teeth and mandibles
    64. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation
    65. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells
    66. Bmi-1 downregulates the expression of NF-HEV, a novel cellular protein exhibiting growth suppressive activity
    67. Bmi-1 enhances the radioresistance of cells by suppressing the expression of NADPH oxidase genes
    68. Bmi-1 expression as a new independent prognostic marker of hepatocellular carcinoma
    69. Bmi-1 expression inversely correlates with differentiation but not clinical outcome or CDKN2a expression in Ewing sarcoma family of tumors
    70. Bmi-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia
    71. Bmi-1 expression is increased in dogs suffering from immune-mediated haemolytic anaemia
    72. Bmi-1 expression is inversely correlated with the grading of renal clear cell carcinoma
    73. Bmi-1 Expression Is Useful To Design Therapy and To Predict Prognosis in Patients with Acute Myeloid Leukemia.
    74. Bmi-1 expression modulates non-small cell lung cancer progression
    75. Bmi-1 expression of bone marrow mesenchymal stem cells induced by fluid shear stress mediated with Akt signal molecule
    76. Bmi-1 expression predicts prognosis in salivary adenoid cystic carcinoma and correlates with epithelial-mesenchymal transition–related factors
    77. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue
    78. Bmi-1 Expression Predicts the Progression of Malignant Hematopoietic Stem Cells in Myelodysplastic Syndrome.
    79. Bmi-1 extends proliferative potential of human bronchial epithelial cells while retaining their mucociliary differentiation capacity
    80. Bmi-1 extends the life span of normal human oral keratinocytes by inhibiting the TGF-β signaling
    81. Bmi-1 extends the replicative life span of normal human oral keratinocytes independently of p16INK4A
    82. Bmi-1 functions as a cooperative oncogene in Ewing’s sarcoma.
    83. Bmi-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas
    84. Bmi-1 gene and radiation resistance
    85. Bmi-1 Gene Expression and Its Significance in 66 Leukemia Patients
    86. Bmi-1 gene expression and its significance in leukemia
    87. Bmi-1 gene in regulation of proliferation and survival of human prostate cancer
    88. Bmi-1 induces radioresistance in MCF-7 mammary carcinoma cells
    89. Bmi-1 inhibition by PTC-209 induces mitochondrial apoptosis in acute myeloid leukemia cells
    90. Bmi-1 interacts with sMEK1 and inactivates sMEK1-induced apoptotic cell death
    91. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation
    92. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal
    93. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
    94. Bmi-1 is a potential therapeutic target in diffuse intrinsic pontine glioma
    95. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells
    96. Bmi-1 Is Dispensable for the Development of Acute Myeloid Leukemia Mediated by MLL-AF9
    97. Bmi-1 is essential for the oncogenic potential in CD133+ human laryngeal cancer cells
    98. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells
    99. Bmi-1 is highly expressed in M0-subtype acute myeloid leukemia
    100. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells
    101. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
    102. Bmi-1 is useful as a novel molecular marker for predicting progression of
    103. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
    104. Bmi-1 mRNA in plasma from breast cancer patients as possible prognosis marker in advanced pathological stages
    105. Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo
    106. Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation
    107. Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
    108. Bmi-1 Overexpression in 32Dcl3 Cells Suppresses Granulocytic Differentiation and Ameliorates Their Growth under IL-3 Diminished Conditions.
    109. Bmi-1 Overexpression Synergizes with p210-BCR-ABL to Induce Stem Cell and Progenitor Transformation.
    110. Bmi-1 plays a critical role in the protection from acute tubular necrosis by mobilizing renal stem/progenitor cells
    111. Bmi-1 promotes drug resistance and cellular invasion in head and neck cancer stem cells
    112. Bmi-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression
    113. Bmi-1 promotes glioma angiogenesis by activating NF-κB signaling
    114. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer
    115. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence …
    116. Bmi-1 promotes self-renewal of radio-and temozolomide (TMZ)-resistant breast cancer cells
    117. Bmi-1 promotes the aggressiveness of glioma via activating the NF-kappaB/MMP-9 signaling pathway
    118. Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells
    119. Bmi-1 promotes the invasion and migration of colon cancer stem cells through the downregulation of E-cadherin
    120. Bmi-1 protects human keratinocytes from ionizing radiation by enhancing DNA repair activity and inhibiting the TGF-b signaling
    121. Bmi-1 Protein Expression in CD34 Positive Acute Myelogenous Leukemia Cells as a Prognostic Factor.
    122. Bmi-1 reduction plays a key role in physiological and premature aging of primary human keratinocytes
    123. Bmi-1 Regulates Autoreactive CD4+ T Cell Survival in Immune Thrombocytopenia Patients
    124. Bmi-1 regulates epithelial-to-mesenchymal transition to promote migration and invasion of breast cancer cells
    125. Bmi-1 Regulates Ex Vivo Self-Renewal of Human Erythroblasts
    126. Bmi-1 regulates extensive erythroid self-renewal
    127. Bmi-1 regulates self-renewal of normal and malignant human mammary stem cells
    128. Bmi-1 regulates self-renewal, proliferation and senescence of human fetal neural stem cells in vitro
    129. Bmi-1 regulates snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells
    130. Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
    131. Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner
    132. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic β-cell proliferation
    133. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1
    134. Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma
    135. Bmi-1 silencing significantly reduces gene expression of DNA damage repair markers in human breast cancer (1047.5)
    136. Bmi-1 siRNA inhibited ovarian cancer cell line growth and decreased telomerase activity
    137. Bmi-1 suppresses contact inhibition and stabilizes YAP in Ewing sarcoma
    138. Bmi-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway
    139. Bmi-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer
    140. Bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis.
    141. Bmi-1-Green Fluorescent Protein (GFP)-Knock-In Mice Reveal the Dynamic Regulation of Bmi-1 Expression in Normal and Leukemic Hematopoietic Cells.
    142. Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels
    143. Bmi-1-siRNA Regulates the Proliferation of K562 Leukemia Cells in vitro and in vivo by PTEN/pAKT Pathway
    144. Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases—elevated Bmi-1 expression in late breast cancer relapses
    145. Bmi-1, stem cells and cancer
    146. Bmi-1, stem cells and prostate carcinogenesis
    147. Bmi-1: a protein expressed in stem cells, specialized cells and tumors of the gastrointestinal tract
    148. Bmi-1: At the crossroads of physiological and pathological biology
    149. Bmi‐1 expression predicts prognosis for patients with gastric carcinoma
    150. Bmi‐1 gene is upregulated in early‐stage hepatocellular carcinoma and correlates with ATP‐binding cassette transporter B1 expression
    151. Bmi‐1 high‐expressing cells enrich cardiac stem/progenitor cells and respond to heart injury
    152. Bmi‑1 induces radioresistance by suppressing senescence in human U87 glioma cells
    153. Bmi‐1 is critical for the proliferation and invasiveness of gastric carcinoma cells
    154. BMI‑1 is important in bufalin‑induced apoptosis of K562 cells
    155. Bmi‐1 is related to proliferation, survival and poor prognosis in pancreatic cancer
    156. BMI‐1 Mediates Estrogen‐Deficiency–Induced Bone Loss by Inhibiting Reactive Oxygen Species Accumulation and T Cell Activation
    157. Bmi‐1 plays a critical role in protection from renal tubulointerstitial injury by maintaining redox balance
    158. Bmi‐1 regulates the migration and invasion of glioma cells through p16
    159. Bmi‐1‐green fluorescent protein‐knock‐in mice reveal the dynamic regulation of bmi‐1 expression in normal and leukemic hematopoietic cells
    160. Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway
    161. BMI‑1, a promising therapeutic target for human cancer
    162. Cadherin switching, Twist, and Bmi-1 expression at the invasive front correlate with aggressive disease in oral squamous cell carcinoma patients: molecular biology …
    163. Can the life span of human marrow stromal cells be prolonged by bmi‐1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation?
    164. Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer
    165. Change of SALL4 and Bmi-1 Expression Levels in Hematologic Malignancies
    166. Characterization and chromosomal localization of the human proto-oncogene Bmi-1
    167. Circulating Bmi-1 mRNA as a diagnostic and prognostic biomarker for non-small cell lung cancer
    168. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients
    169. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer
    170. Clinical implications of Bmi-1 in cancer stem cells of laryngeal carcinoma
    171. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma
    172. Clinicopathological and prognostic significance of Bmi‐1 expression in human cervical cancer
    173. Clinicopathological and Prognostic Significance of Expression of B-Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) Gene and Protein in …
    174. Clinicopathological significance of Bmi-1 overexpression in esophageal cancer: a meta-analysis
    175. Clinicopathological study of Bmi-1 and Mel-18 expression in breast cancer [J]
    176. Cloning of the rat proto-oncogene Bmi-1
    177. Co-expression of Bmi-1 and podoplanin predicts overall survival in patients with squamous cell carcinoma of the head and neck treated with radio (chemo) therapy
    178. Coexpression of Bmi-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease
    179. Coexpression of Bmi-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma
    180. Collagen I regulates the self‐renewal of mouse embryonic stem cells through α2β1 integrin‐and DDR1‐dependent Bmi‐1
    181. Combination of circulating CXCR4 and Bmi-1 mRNA in plasma: A potential novel tumor marker for gastric cancer
    182. Combination of hTERT and Bmi-1, E6, or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their neurogenic …
    183. Combined introduction of Bmi-1 and hTERT immortalizes human adipose tissue-derived stromal cells with low risk of transformation
    184. Consequences of p16 tumor suppressor gene inactivation in mycosis fungoides and Sézary syndrome and role of the Bmi-1 and ras oncogenes in disease …
    185. Consistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma
    186. Construction of antisense Bmi-1 expression plasmid and its inhibitory effect on K562 cells proliferation.
    187. Construction of eukaryotic expression vector targeting Bmi-1 and its influences on proliferation of SW480 cells
    188. Construction of eukaryotic vector Bmi-1 shRNA and its inhibition in Hela cells [J]
    189. Construction of shRNA-Bmi-1 plasmid and its effect on proliferation of ECA109 cells.
    190. Construction, identification and expression of recombinant eukaryotic vector pEGFP-Bmi-1
    191. Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
    192. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1
    193. Copper induces cellular senescence in human glioblastoma multiforme cells through downregulation of Bmi-1
    194. Correlation between Bmi-1 and clinicopathological features of colorectal cancer
    195. Correlation between Bmi-1, p16 gene expressions and replicative senescence of fetal bone marrow-derived mesenchymal stem cells
    196. Correlation between Rhoc and Bmi-1 invasiveness and migration and prognostic of esophageal squamous carcinoma
    197. Correlation of Bmi-1 expression and telomerase activity in human ovarian cancer
    198. Correlation of HSP70, P53 and Bmi-1 in hepatitis, cirrhosis and hepatocellular carcinoma
    199. Correlations of Bmi-1 expression and telomerase activity in ovarian cancer tissues
    200. Correspondence re: S. Beá et al., Bmi-1 Gene Amplification and Overexpression in Hematological Malignancies Occur Mainly in Mantle Cell Lymphomas. Cancer Res …
    201. Cow’s Milk Yogurt Modulate Expression of STAT5, Bmi-1 and LGR-5 in ileum of Indomethacine-Induced Inflammatory Bowel Disease (IBD) in Rats.
    202. Crucial Role of the Polycomb Group Gene Product Bmi-1 in the Maintenance of Self-Renewing Hematopoietic Stem Cells
    203. Defects in mesenchymal stem cell self‐renewal and cell fate determination lead to an osteopenic phenotype in Bmi‐1 null mice
    204. Deletion of Bmi-1 gene leads to skin aging in mice [J]
    205. Depletion of Bmi-1 enhances 5-fluorouracil-induced apoptosis and autophagy in hepatocellular carcinoma cells
    206. Deregulation of Bmi-1 is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma
    207. Detection of CD133, Bmi‐1, and ABCG2 in ameloblastic tumors
    208. Detection of circulating Bmi‐1 mRNA in plasma and its potential diagnostic and prognostic value for uterine cervical cancer
    209. Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers
    210. Diagnostic value of combined detection of autoantibodies against p53 and Bmi-1 in lung cancer
    211. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma
    212. DIPG-13. SENSITIVITY OF DIPG CELLS TO Bmi-1 MODULATOR PTC596 IS INDEPENDENT OF EZH2 ACTIVITY
    213. DIPG-18. VALIDATION OF Bmi-1 AS A THERAPEUTIC TARGET IN DIFFUSE INTRINSIC PONTINE GLIOMA
    214. Direct serum assay for cell-free Bmi-1 mRNA and its potential diagnostic and prognostic value for colorectal cancer
    215. Distinct Bmi-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation
    216. Doublecortin-like kinase 1 (DCLK1) regulates B cell-specific moloney murine leukemia virus insertion site 1 (Bmi-1) and is associated with metastasis and prognosis …
    217. Down-regulation of Bmi-1 by RNA interference in Jurkat cells
    218. Down-Regulation of Bmi-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia.
    219. Down‐regulation of BMI‐1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells
    220. Downregulated miR-45 Inhibits the G1-S Phase Transition by Targeting Bmi-1 in Breast Cancer
    221. Downregulation of Bmi-1 By the Small Molecule PTC596 Induces Mitochondrial Apoptosis in Mantle Cell Lymphoma
    222. Downregulation of Bmi-1 enhances 5-fluorouracil-induced apoptosis in nasopharyngeal carcinoma cells
    223. Downregulation of Bmi-1 enhances chemosensitivity in breast cancer cells.
    224. Downregulation of Bmi-1 is associated with suppressed tumorigenesis and induced apoptosis in CD44+ nasopharyngeal carcinoma cancer stem-like cells
    225. Downregulation of Bmi-1 suppresses epithelial‑mesenchymal transition in melanoma
    226. Downregulation of hsa_circ_0007534 restricts the proliferation and invasion of cervical cancer through regulating miR-498/Bmi-1 signaling
    227. Downregulation of miR-221,-30d, and-15a contributes to pathogenesis of prostate cancer by targeting Bmi-1
    228. Drosophila genes Posterior Sex Combs and Suppressor two of zeste encode proteins with homology to the murine Bmi-1 oncogene
    229. Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone
    230. Effect of 5-fluorouracil on the expression of Oct4 and Bmi-1 in human breast cancer cell line MCF7
    231. Effect of 5-FU on expression of Bmi-1, Sca-1 and Oct-4 in human breast cancer cell line MDA-MB-468
    232. Effect of Bmi-1 gene overexpression on proliferation of human gastric mucosal epithelial cell line GES-1 [J]
    233. Effect of Bmi-1 on radiosensitization of esophageal carcino-ma cells after silencing of Bmi-1 gene
    234. Effect of Bmi-1-mediated NF-κB signaling pathway on the stem-like properties of CD133+ human liver cancer cells
    235. Effect of gene silencing of Bmi-1 on proliferation regulation of CD44+ nasopharyngeal carcinoma cancer stem-like cells
    236. Effect of shRNA-Mediated Gene Silencing of Bmi-1 Expression on Chemosensitivity of CD44+ Nasopharyngeal Carcinoma Cancer Stem-Like Cells
    237. Effect of silencing Bmi-1 by RNA interference on function of K562 cell line
    238. Effect of silencing Bmi-1 expression in reversing cisplatin resistance in lung cancer cells and its mechanism
    239. Effect of siRNA-mediated silencing Bmi-1 gene expression on the proliferation of lung cancer cell line A549 in vitro and in vivo
    240. Effect of siRNA-mediated silencing Bmi-1 gene expression on the proliferation of lung cancer cell line A549 in vitro and in vivo
    241. Effect of siRNA‐mediated silencing of Bmi‐1 gene expression on HeLa cells
    242. Effects of antisense Bmi-1 RNA on the proliferation of lung cancer cell line A549
    243. Effects of Bmi-1 gene suppression on nasopharyngeal carcinoma cell biology behavior
    244. Effects of Bmi-1 on progression of human glioma SNB19 cells [J]
    245. Effects of Bmi-1 over-expression on HOX family expression and cell cycle in HeLa cells
    246. Effects of Bmi-1 RNAi gene on laryngeal carcinoma Hep-2 cells
    247. Effects of Bmi-1 RNAi gene on laryngeal carcinoma Hep-2 cells [J]
    248. Effects of Bmi-1-siRNA on proliferation of lung adenocarcinoma SPC-A1 cells and its mechanism
    249. Effects of combined c-myc and Bmi-1 siRNAs on the growth and chemosensitivity of MG-63 osteosarcoma cells
    250. Effects of RNA interfering Bmi-1 on glioma cells proliferation
    251. Effects of siRNA silencing of Bmi-1 expression on proliferation of Hela cells
    252. Effects of targeted nano-delivery systems combined with hTERT-siRNA and Bmi-1-siRNA on MCF-7 cells
    253. Efficient immortalization of primary human cells by p16INK4a‐specific short hairpin RNA or Bmi‐1, combined with introduction of hTERT
    254. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival
    255. Elevated Serum IL-6, IL-8, Monocyte Chemoattractant Protein-1, CRP, and IFN-Levels in 10-to 11-Year-Old Boys with Increased BMI
    256. Enforced Expression of Bmi-1 in Postnatal Human CD34+ Cells Promotes Erythroid Differentiation
    257. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1
    258. Enhanced Self-Renewal of Hematopoietic Stem Cells Mediated by the Polycomb Gene Product, Bmi-1.
    259. Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer
    260. Establishment of a U266 cell line with stable Bmi-1 silencing by lentivirus-mediated RNA interference
    261. Establishment of detection method for serum circulating Bmi-1 mRNA and its application in diagnosis of colorectal cancer
    262. EVALUATING THE EXPRESSION OF Bmi-1, AS A NEW MOLECULAR MARKER IN DIAGNOSIS AND CHISSIFICATION OF BLADDER TUMORS
    263. Evaluating the expression of Bmi-1, as a new molecular marker in diagnosis and classification of bladder tumors
    264. Evaluating the mechanism and therapeutic potential of PTC-028, a novel inhibitor of Bmi-1 function in ovarian cancer
    265. Evaluation of potential prognostic value of Bmi-1 gene product and selected markers of proliferation (Ki-67) and apoptosis (p53) in the neuroblastoma group of …
    266. Evaluation of the expression of Bmi-1 stem cell marker in sinonasal melanomas and its correlation with the expression of cell cycle proteins
    267. Ewing tumors that do not over-express Bmi-1 are a distinct molecular subclass with variant biology: A report from the Children’s Oncology Group
    268. Ewing tumors that do not overexpress Bmi-1 are a distinct molecular subclass with variant biology: a report from the Children’s Oncology Group
    269. Ex-Vivo Expansion of Human Cord Blood CD34+ Cells by Overexpression of Bmi-1.
    270. Exacerbation of acute leukemia bearing isolated i (17q) along with proliferation of blasts with high Bmi-1 expression
    271. Expression and associations of TRAF1, Bmi-1, ALDH1, and Lin28B in oral squamous cell carcinoma
    272. Expression and Clinical Significance of Bmi-1 and P14 in Extranodal NK/T-cell Lymphoma
    273. Expression and clinical significance of Bmi-1 in colorectal cancer
    274. Expression and clinical significance of Bmi-1 in gastric carcinoma
    275. Expression and Clinical Significance of Bmi-1 in Rectal Cancer
    276. Expression and Clinical Significance of Bmi-1 Oncogene and Its Protein in Cervical Cancer
    277. Expression and Clinical Significance of Bmi-1 Oncogene in Breast Cancer
    278. Expression and Clinical Significance of Bmi-1 Oncogene in Gastric Carcinoma
    279. Expression and clinical significance of Bmi-1 protein and hTERT protein in non-small cell lung cancer.
    280. Expression and clinical significance of Bmi-1, Caspase-8 protein in primary epithelia ovarian cancer
    281. Expression and clinical significance of Bmi-1, Caspase-8 protein in primary epithelia ovarian cancer [J]
    282. Expression and clinical significance of Bmi-1, cyclin D1 and p16 in gastric carcinoma [J]
    283. Expression and clinical significance of Bmi-1, Mdm2 and Ki-67 in extrahepatic biliary duct carcinoma.
    284. Expression and clinical significance of Bmi-1, Podoplanin and p53 in human thymic epithelial tumor
    285. Expression and clinical significance of Bmi-1, Podoplanin and p53 in human thymic epithelial tumor [J]
    286. Expression and clinicopathological significance of Mel-18 and Bmi-1 in esophageal squamous cell carcinoma
    287. Expression and clinicopathological significance of Mel-18 and Bmi-1 mRNA in gastric carcinoma
    288. Expression and distribution patterns of the stem cell marker, nestin, and the stem cell renewal factor, Bmi-1, in normal human nasal mucosa and nasal polyps
    289. Expression and significance of Bmi 1 in pancreatic carcinoma
    290. Expression and significance of Bmi-1 and P16 in colorectal carcinoma patients.
    291. Expression and significance of Bmi-1 and P16 in colorectal carcinoma.
    292. Expression and Significance of Bmi-1 and PCNA in Cutaneous Squamous Cell Carcinoma
    293. Expression and significance of Bmi-1 in breast cancer
    294. Expression and Significance of Bmi-1 in Cervical Cancer
    295. Expression and significance of Bmi-1 in endometrial carcinoma
    296. Expression and significance of Bmi-1 in hepatocellular carcinoma tissue and portal vein tumor thrombus
    297. Expression and significance of Bmi-1 in human colon carcinoma [J]
    298. Expression and significance of Bmi-1 mRNA in acute myeloid leukemia with real-time fluorescent quantitative polymerase chain reaction
    299. Expression and significance of Notch1 and Bmi-1 protein in lung cancer tissue
    300. Expression and significance of the Bmi-1 gene in hepatocellular carcinoma
    301. Expression and significances of Bmi-1 and c-myc in diffuse large B-cell lymphoma
    302. Expression changes in EZH2, but not in Bmi-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer
    303. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer
    304. Expression of an alternate splice form of Bmi-1 in multiple myeloma
    305. Expression of B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 (Bmi-1) and WW Domain-Containing Oxidoreductase (WWOX) in Liver …
    306. Expression of Bmi-1 and EZH2 in tissues adjacent to human epithelial ovarian cancer cells of orthotopic implantation in nude mice
    307. Expression of Bmi-1 and hTERT in breast cancer cell line MDA-MB-468 and their relationship with apoptosis [J]
    308. Expression of Bmi-1 and Mel-18 in breast tissue-a diagnostic marker in patients with breast cancer
    309. Expression of Bmi-1 and p16 gene in transitional cell carcinoma of bladder
    310. Expression of Bmi-1 and p16 in cervical carcinoma carcinogenesis progression and its significance [J]
    311. Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma
    312. Expression of Bmi-1 Gene in Children with Acute Leukemia and Its Clinical Significance
    313. Expression of Bmi-1 Gene in Children with Acute Leukemia and Its Clinical Significance [J]
    314. Expression of Bmi-1 gene in esophageal carcinoma cell EC9706 and its effect on cell cycle, apoptosis and migration
    315. Expression of Bmi-1 gene in papillary thyroid carcinoma
    316. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis
    317. Expression of Bmi-1 in gastric cancer and its clinical significance
    318. Expression of Bmi-1 in gastric cancer and its significance [J]
    319. Expression of Bmi-1 in NSCLC and Its Relationship to Clinicopathologic Characters
    320. Expression of Bmi-1 in pediatric brain tumors as a new independent prognostic marker of patient survival
    321. Expression of Bmi-1 is a prognostic marker in bladder cancer
    322. Expression of Bmi-1 Protein in Esophageal Squamous Cell Carcinoma Tissue and Its Relationship with Invasion and Metastasis
    323. Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients
    324. Expression of Bmi-1 Stem Cell Marker and P16 in Sinonasal Melanoma and Its Correlation with Cellular Proliferation
    325. Expression of Bmi-1 Stem Cell Marker and P16 in Sinonasal Melanoma and Its Correlation with Cellular Proliferation
    326. Expression of Bmi-1, p14 ARF and Mdm2 and their clinical significance in colorectal carcinoma
    327. Expression of Bmi-1, P16, and CD44v6 in uterine cervical carcinoma and its clinical significance
    328. Expression of BMI‐1 in normal skin and inflammatory and neoplastic skin lesions
    329. Expression of c-myc, Bmi-1, serum insulin-like growth factor-Ⅰ and insulin-like growth factor binding protein-3 and their significances in diffuse large B-cell lymphoma
    330. Expression of CD44, CD44v9, ABCG2, CD24, Bmi‑1 and ALDH1 in stage I and II oral squamous cell carcinoma and their association with clinicopathological …
    331. EXPRESSION OF OCT-4, SOX-2, NANOG, NUCLEOSTEMIN, Bmi-1 AND SOX-9 SELF RENEWAL GENES IN HUMAN UMBILICAL CORD VEIN MESENCHYMAL …
    332. Expression of p120 catenin and Bmi-1 and their clinical significance in invasive mammary ductal carcinoma
    333. Expression of Polycomb Group Proteins EZH2 and Bmi-1 During Progression of Esophageal Squamous Intraepithelial Neoplasia
    334. Expression of polycomb protein BMI‐1 maintains the plasticity of basal bronchial epithelial cells
    335. Expression of Polycomb-group (PcG) protein Bmi-1 predicts prognosis in patients with acute myeloid leukemia
    336. Expression of Proteins P16INK 4a, P53 and Bmi-1 in Hematopoietic Stem Cells of Patients with MDS. the Role of Cellular Senescence.
    337. Expression of SALL4 and Bmi-1 mRNA in acute leukemia
    338. Expression of stemness gene Bmi-1 in hepatocellular carcinoma
    339. Expression of the p16INK4a gene product, methylation of the p16INK4a promoter region and expression of the polycomb-group gene Bmi-1 in squamous cell lung …
    340. Expression of the polycomb group gene Bmi-1 in the early chick embryo
    341. Expression Of The Stem Cell Markers ABCG2/BCRP, Bmi-1, P63alpha And C/EBPdelta In The Normal Human Cornea: An Immunohistochemical Study
    342. Expression of VEGF-A/C, VEGF-R2, PDGF-α/β, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma
    343. Expression patterns of ABCG2, Bmi-1, Oct-3/4, and Yap in the developing mouse incisor
    344. Expression patterns of Bmi‐1 and p16 significantly correlate with overall, disease‐specific, and recurrence‐free survival in oropharyngeal squamous cell carcinoma
    345. Expression patterns of USP22 and potential targets Bmi-1, PTEN, p-AKT in non-small-cell lung cancer
    346. Expressions and clinical significances of Bmi-1 in human cervical carcinoma [J]
    347. Expressions and clinicopathological significances of Bmi-1 and PADI4 in esophageal squamous cell car-cinoma
    348. EXPRESSIONS OF Bmi-1 AND C-myc PROTEINS IN NON-SMALL CELL LUNG CANCER AND THEIR CORRELATION [J]
    349. EXPRESSIONS OF Bmi-1 AND hTERT PROTEIN IN GASTRIC CARCINOMA
    350. Expressions of Bmi-1 and p53 and significance in colon cancer
    351. EXTH-27. VALIDATION OF Bmi-1 AS A THERAPEUTIC TARGET IN DIFFUSE INTRINSIC PONTINE GLIOMA
    352. EZH2-mediated, but not Bmi-1, epigenetic alteration may be associated with the accelerated cell proliferation and malignant step in IPMN.
    353. flvi-2, a target of retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes Bmi-1.
    354. FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression
    355. FoxM1c counteracts oxidative stress-induced senescence in mouse embryonic fibroblasts by up-regulation of Bmi-1 expression
    356. Fuel shipment experience, fuel movements from the Bmi-1 transport cask
    357. Glucagon-like peptide-2 requires a full complement of Bmi-1 for its proliferative effects in the murine small intestine
    358. Harnessing the power of stem cell self-renewal pathways in cancer: Dissecting the role of Bmi-1 in Ewing’s sarcoma initiation and maintenance
    359. HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression
    360. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells
    361. HER 2 NEU and Bmi 1 gene expression in Invasive Ductal Carcinoma Breast and Its correlation with hormone receptors and other known prognostic factors
    362. Hes1 promotes cell proliferation and migration by activating Bmi-1 and PTEN/Akt/GSK3β pathway in human colon cancer
    363. Heterozygous knockout of the Bmi-1 gene causes an early onset of phenotypes associated with brain aging
    364. High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma
    365. Id1 and NF-κB promote the generation of CD133+ and Bmi-1+ keratinocytes and the growth of xenograft tumors in mice
    366. Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex
    367. Identification and characterization of Bmi-1-responding element within the human p16 promoter
    368. Identification of a polymorphism in the RING finger of human Bmi-1 that causes its degradation by the ubiquitin–proteasome system
    369. Identification Of Bmi-1 As A Prognostic Marker For Differentiation And Invasiveness Of Retinoblastomas
    370. Identification of genes differentially regulated by E6 in human oral keratinocytes expressing exogenous Bmi-1
    371. IGF-1R and Bmi-1 expressions in lung adenocarcinoma and their clinicopathologic and prognostic significance
    372. Immortalization of cementoblast progenitor cells with Bmi‐1 and TERT
    373. Immortalization of human oral keratinocytes by Bmi-1 and HPV type 16 E6 requires telomerase activation domain of E6
    374. Immortalized Human Placenta Derived Mesenchymal Cells by Transfection with Bmi-1 Lost the Abilitiy To Differencitate into Cell Types of Osteocytic, Condoricytic and …
    375. Immunohistochemical expression and prognostic relevance of Bmi-1, a stem cell factor, in epithelial ovarian cancer
    376. Immunohistochemical expression of Bmi-1, S100A4, and claudin-1 in breast cancer
    377. Immunohistochemical expression of cytokeratin 15, cytokeratin 19, follistatin, and Bmi‐1 in basal cell carcinoma
    378. Impaired GLP-1 response predicts prediabetes in obese PCOS with adverse metabolic phenotype independent of BMI
    379. Impaired odontogenic differentiation of senescent dental mesenchymal stem cells is associated with loss of Bmi-1 expression
    380. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas
    381. Implication of USP22 in the regulation of Bmi-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas
    382. In Chronic Myeloid Leukemia Cytotoxic T Cell Responses to Bmi-1 Protein Correlate with Higher Expression of Bmi-1 in Leukemia Progenitors, and May Contribute to …
    383. In vitro study of joint intervention of E-cad and Bmi-1 mediated by transcription activator-like effector nuclease in nasopharyngeal carcinoma
    384. Increased expression of the EZH2 polycomb group gene in Bmi-1-positive neoplastic cells during bronchial carcinogenesis
    385. Increased global long interspersed nucleotide element 1 DNA methylation in type 2 diabetes mellitus individuals relates to lower blood pressure and BMI
    386. Increased levels of circulating and tissue mRNAs of Oct-4, Sox-2, Bmi-1 and Nanog is ESCC patients: potential tool for minimally invasive cancer diagnosis
    387. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma
    388. Independent prognostic value of the basal‐like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI‐1
    389. Inhibiting effect of small interfering RNA of Bmi-1 on the proliferation of breast cancer MCF-7 cells in vitro [J]
    390. Inhibition effect of antisense Bmi-1 on Jurkat cells
    391. Inhibition of Bmi-1 suppressed the tumorigenicity of oral cancer-derived ALDH1-positive cells
    392. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1
    393. Inhibitory Effect of Bmi-1 Knockdown on Growth of Human SO-RB_ (50) Cells In Vitro [J]
    394. Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma
    395. Interaction of hedgehog and notch pathways, and Bmi-1 in the regulation of human breast stem cell self-renewal
    396. Intracellular redox status determines self-renewal activity of breast cancer stem-like cells through activation of Nrf2-mediated FoxO3a-Bmi-1 signaling
    397. Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor …
    398. Investigating the role of Bmi-1 in liver growth and function
    399. Investigating the roles of Bmi-1 and IGF-1 in promoting ESFT survival
    400. Investigation of the Correlation Between the Expression and Pathological Eharaeteristies of Bmi-1 Protein in Breast Cancer